Harbor Capital Advisors Inc. Has $13.01 Million Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Harbor Capital Advisors Inc. lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 12.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 145,379 shares of the medical equipment provider's stock after buying an additional 16,466 shares during the quarter. Harbor Capital Advisors Inc. owned about 0.21% of Lantheus worth $13,006,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB acquired a new stake in shares of Lantheus in the third quarter valued at approximately $25,000. Signaturefd LLC boosted its holdings in Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 92 shares during the last quarter. UMB Bank n.a. raised its holdings in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after purchasing an additional 126 shares during the last quarter. Kathleen S. Wright Associates Inc. acquired a new position in Lantheus during the 3rd quarter valued at about $51,000. Finally, GAMMA Investing LLC grew its position in shares of Lantheus by 45.5% during the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock worth $51,000 after buying an additional 146 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Analyst Ratings Changes

A number of brokerages have issued reports on LNTH. The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective on the stock. JMP Securities reduced their target price on Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a report on Thursday, November 7th. Truist Financial restated a "buy" rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, StockNews.com cut Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $131.86.

Lantheus Trading Up 2.0 %

NASDAQ LNTH traded up $1.88 during midday trading on Friday, hitting $95.88. The company had a trading volume of 645,895 shares, compared to its average volume of 835,166. The firm has a 50-day moving average price of $90.63 and a 200-day moving average price of $99.30. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The company has a market capitalization of $6.67 billion, a PE ratio of 15.95 and a beta of 0.46.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.